Our Portfolio

UT Speech Recognition

His novel acoustic model, developed in his lab within the Department of Computer Science at the University of Toronto, significantly improves voice-enabled technologies by making them better at understanding different speakers in noisy environments. The technology is being licensed to fluent.ai, an incubating venture within TandemLaunch’s portfolio. Read more

High-Efficiency, High-Power Ultrasound Transducer

The Challenges: Handheld and mobile imaging systems are the fastest growing market segment within the medical ultrasound industry, both in developed and developing markets. Among the major competitive factors, image quality, device weight and battery life are currently major drivers. There are traditionally limiting trade offs between these factors, with each manufacturer forced to choose which axis to maximize at the expense of others. The Solution: This new method of driving piezoelectric ultrasound transducers results from fundamental physical insights into the behavior ... Read more


Thotra's technology transforms hard-to-understand speech of individuals with disorders or accents to be clear. It is a mobile technology with a cloud-based platform available for individuals, speech therapists and language instructors, or may be embedded for enterprise use. Read more


VitalHub develops mobile healthcare solutions that allow clinicians to rapidly access the most comprehensive and relevant information about their patients. Designed by and for clinicians, VitalHub provides healthcare professionals with a unified and customizable view of their patients, while also saving time and reducing the risk of errors. Read more

Triphase Accelerator

Triphase Accelerator is a private drug development company with a primary focus on oncology and with operations in Toronto and San Diego. Triphase Accelerator is dedicated to advancing novel compounds through Phase 2 proof-of-concept clinical studies using a unique, science-based, high-quality model that is faster and more cost-effective than traditional pharmaceutical and biotech industry drug development approaches. Triphase Accelerator was spun out of the Ontario Institute for Cancer Research (OICR), with support from the Fight Against Cancer Innovation Trust (FACIT), MaRS ... Read more

ScarX Therapeutics

ScarX Therapeutics (ScarX) is a Canadian biotechnology company, founded in partnership with The Hospital for Sick Children and MaRS Innovation, that discovers and develops innovative treatments for dermal scarring (fibrosis). The company’s lead candidate will be the first topical prescription cream to treat and prevent post-surgical scarring, with the eventual goal of creating better functional and cosmetic outcomes for patients. In 2015, BioCentury featured ScarX Therapeutics as an emerging company to watch. Read more

Kaypok Inc.

Kaypok's high-performance algorithm transform noisy, unstructured big data by automatically filtering and categorizing text regardless of source (e.g., email, survey results, social interactions, etc.). Kaypok allows companies to determine the root causes and underlying emotions driving their customers’ feedback. Read more

Kapplex Inc.

Kapplex Inc. is a point-of care company specializing in diagnosis of most common infectious diseases. They design, develop, manufacture and market point-of-care diagnostic platforms suitable for use in retail clinics, doctor’s offices, urgent care, and emergency rooms. Their goal is ‘patient-centric’ care by enabling clinicians to rapidly and accurately diagnose a disease at a patient’s first visit. This will significantly improve the coarse of treatment and reduce health care costs. Kapplex was acquired by Miroculus Inc. in 2016. Read more

Flybits Inc.

Flybits was founded in 2013 to commercialize the pioneering work on context-aware computing and ubiquitous computing done by Dr. Hossein Rahnama and his team at Ryerson University. Flybits today is a passionate and innovative team with offices in Palo Alto, CA and Toronto, ON, dedicated to putting context at the service of app developers and the enterprises they support. Their mission is to create the standard software that makes it easy to gather all available data that make up a user's context, ... Read more

Encycle Therapeutics

Encycle is exploiting a unique platform technology that enables rapid synthesis of small, drug-like macrocycles. Encycle’s scientific founder, Dr. Andrei Yudin, pioneered a technique to synthesize macrocycles using amphoteric reagents called aziridine aldehydes. Aziridine aldehyde-based macrocycles, or nacellins, possess several advantages over macrocycles synthesized using traditional chemistry, such as a significantly enhanced ability to passively diffuse across cell membranes. This attribute opens up new therapeutic avenues, including the potential to generate orally bioavailable modulators of protein-protein interactions, as well as potent modulators ... Read more
Page 1 of 612345...Last »